Platelet findings in 22q11.2 Deletion Syndrome correlate with disease manifestations but do not correlate with GP1b surface expression

Competing Interest Statement

D.M.M-M. serves as a Trustee for the 22q11.2 Society. M.P.L. is a consultant for Novartis, Dynamed (EBESCO), Octapharma, Sysmex, CSL Behring, Dova, Shionogi, Sobi, Bayer, and the Department of Justice. She is a member of an advisory board for Novartis, Rigel, Dova, Principia, and Argenx. She has received research funding from OctaPharma, Sobi, Janssen, Argenx, Dova, Principia, Novartis, Astra Zeneca, Quansys, and Sysmex but there is no clear way that any of these organizations would gain or lose financially though this publication. She serves as a medical advisor for the Platelet Disorder Support Association, the 22q11.2 Society, and the Cornelia de Lange Syndrome Foundation. The remaining authors declare no conflicts of interest.

Funding Statement

This study was funded by the NIH: UO1MH191739, U01MH087636, PO1HD070454.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The Institutional Review Board at the Children's Hospital of Philadelphia gave ethical approval for this work.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes